Sana Biotechnology (SANA) Net Cash Flow (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Net Cash Flow data on file, last reported at $11.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 138.39% year-over-year to $11.9 million; the trailing twelve-month figure through Mar 2026 stood at -$12.3 million (up 84.69% YoY), and the FY2025 full-year result was -$55.3 million, down 829.81% from the prior year.
• Net Cash Flow climbed to $11.9 million in Q1 2026, from -$31.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $43.5 million in Q1 2024 to a low of -$64.5 million in Q1 2022.
• A 5-year average of -$10.2 million and a median of -$12.0 million in 2023 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 502.99% in 2025, while the deepest fall reached 5624.04% in 2025.
• Tracing SANA's Net Cash Flow over 5 years: stood at $13.4 million in 2022, then slumped by 360.25% to -$34.9 million in 2023, then soared by 101.63% to $570000.0 in 2024, then sank by 5624.04% to -$31.5 million in 2025, then surged by 137.89% to $11.9 million in 2026.
• Business Quant data shows SANA's Net Cash Flow at $11.9 million in Q1 2026, -$31.5 million in Q4 2025, and $32.1 million in Q3 2025.